KTOV - Kitov Pharma Ltd

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.8600
+0.0200 (+2.38%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close0.8400
Open0.8200
Bid0.7800 x 1800
Ask0.9300 x 800
Day's Range0.8224 - 0.8600
52 Week Range0.5600 - 2.9200
Volume37,073
Avg. Volume552,939
Market Cap16.256M
Beta (3Y Monthly)3.87
PE Ratio (TTM)N/A
EPS (TTM)-0.3660
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.00
Trade prices are not sourced from all markets
  • GlobeNewswirelast month

    Kitov Receives Notice of Allowance for Additional U.S. Patent Covering its Commercial Product Consensi™

    Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a pharmaceutical company focused on advancing first-in-class combination oncology therapies to overcome tumor drug resistance, increase treatment response rate, and slow tumor progression, today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office for its Patent Application 16/008,538, “Celecoxib and Amlodipine formulation and methods of making the same,” covering the proprietary formulation of Consensi™, Kitov’s commercial-stage product for the simultaneous treatment of osteoarthritis pain and hypertension. The patent application was filed jointly with Dexcel Pharma Ltd., Kitov’s manufacturing partner for Consensi™, which has provided Kitov with perpetual, royalty-free, license rights for the use of the patent in connection with distribution of Consensi™ in the U.S.

  • GlobeNewswirelast month

    Kitov to Present Clinical Development Plan for Oncology Candidate NT-219 at the 18th MIXiii-BIOMED Conference

    Kitov Pharma Ltd. (the “Company” or “Kitov”) (NASDAQ/TASE: KTOV), a pharmaceutical company focused on advancing first-in-class combination oncology therapies to overcome tumor drug resistance, increase treatment response rate, and slow tumor progression, today announced that its CEO, Isaac Israel, will present at 18th MIXiii-BIOMED Conference and Exhibition, the leading annual international healthcare industry meeting in Israel, to be held on May 14-16, 2019 in Tel Aviv, Israel. The oral presentation will give an overview of Kitov’s clinical development plans for its oncology candidate NT-219, including disclosing its first indication for a phase 1/2 clinical trial and trial design.

  • GlobeNewswirelast month

    Kitov Announces Retirement of Founder and Executive Chairman Dr. Paul Waymack

    Kitov Pharma Ltd. (the “Company” or “Kitov”) (NASDAQ/TASE: KTOV), a pharmaceutical company focused on advancing first-in-class combination oncology therapies to overcome tumor drug resistance, increase treatment response rate, and slow tumor progression, today announced the retirement of its chairman of the board and chief medical officer, Dr. John Paul Waymack. Dr. Waymack will step down from all executive positions and from the board of directors, but will continue to serve as a medical and regulatory advisor to the Company.

  • GlobeNewswire2 months ago

    Kitov Announces Key Milestone in FameWave Acquisition

    Kitov Pharma Ltd. (NASDAQ/TASE: KTOV), an innovative pharmaceutical company developing first-in-class combination oncology therapies, today announces a key milestone in the acquisition of FameWave Ltd., following signature of a clinical collaboration agreement between FameWave and Bristol Myers Squibb (BMY) for their planned Phase 1/2 clinical trials to evaluate the combination of CM-24, a monoclonal antibody targeting the novel immune checkpoint carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) with nivolumab (Opdivo®), a PD-1 inhibitor, in patients with non-small cell lung cancer (NSCLC). “We look forward to completing the acquisition of FameWave and advancing CM-24 studies in the clinic,” said Isaac Israel, chief executive officer of Kitov.

  • GlobeNewswire2 months ago

    FameWave Announces Clinical Collaboration with Bristol Myers Squibb for the Planned Phase 1/2 Trial in Non-Small Cell Lung Cancer to Evaluate Immuno-Oncology Candidate CM-24 in Combination with Nivolumab (Opdivo®)

    TEL AVIV, Israel, April 12, 2019 -- FameWave Ltd. a privately held biopharmaceutical company developing CM-24, which is being acquired by Kitov Pharma Ltd.  (NASDAQ/TASE:.

  • ACCESSWIRE3 months ago

    Potential Milestones Coming for Kitov Pharma and Product Commercialization Plans

    NEW YORK, NY / ACCESSWIRE / March 18, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • ACCESSWIRE3 months ago

    These Four Healthcare Stocks Could Test March Highs

    Given that the success of the healthcare industry is dependent on companies meeting the demands of patients who simply want to live healthy lives, any company taking a patient-centric focus to their healthcare framework has seen impressive gains in the first few months of 2019. Investors looking for potential opportunities could benefit from keeping tabs on the healthcare industry. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Hancock Jaffe Laboratories Inc (HJLI), Kitov Pharmaceuticals Ltd (KTOV), and Auris Medical Holding AG (EARS) are 4 healthcare companies heating up on Thursday.

  • GlobeNewswire3 months ago

    Kitov to Acquire Clinical Stage Candidate CM-24 Creating a Transformational Immuno-Oncology Company

    Kitov Pharma (NASDAQ/TASE: KTOV), an innovative pharmaceutical company, today announced it has signed an agreement to acquire FameWave Ltd., a privately held biopharmaceutical company developing CM-24, a clinical stage monoclonal antibody targeting CEACAM1, a novel immune checkpoint. Kitov is planning initiation of a Phase I/II study in early 2020 to evaluate the safety and efficacy of CM-24 in combination with an anti PD-1 inhibitor.

  • GlobeNewswire4 months ago

    Kitov Pharma Reports Year End 2018 Financial Results and Provides Business Update

    TEL AVIV, Israel, Feb. 07, 2019 -- Kitov Pharma (NASDAQ/TASE: KTOV), an innovative pharmaceutical company, today reported its unaudited financial results for the year ended.

  • ACCESSWIRE5 months ago

    A Biotech Play You Can't Afford To Miss

    HENDERSON, NV / ACCESSWIRE / January 21, 2019 / Biotechnology companies have seen a ton of interest from Big Pharma so far in 2019. While it's not easy to project who may be next, there are several biotech ...

  • GlobeNewswire5 months ago

    Kitov Closes $6 Million Registered Direct Offering

    TEL-AVIV, Israel, Jan. 18, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (NASDAQ/TASE: KTOV), an innovative pharmaceutical company, today announced the closing of its previously announced registered direct offering of 3,428,572 American Depositary Shares (ADS) at a purchase price of $1.75 per ADS, for gross proceeds of $6 million. Kitov also issued unregistered warrants to purchase up to 2,571,430 ADSs. The ADSs described above were offered pursuant to a shelf registration statement on Form F-3 (File No. 333-215037), which was declared effective by the United States Securities and Exchange Commission (the “SEC”) on December 14, 2016.

  • ACCESSWIRE5 months ago

    Small Caps Soaring Off of Bottoms

    HENDERSON, NV / ACCESSWIRE / January 18, 2019 / Small cap stocks give investors the opportunity at huge gains relatively quickly. Due to their low price and volatility, it is a space where investors can ...

  • Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY
    Zacks5 months ago

    Pharma Stock Roundup: Regulatory Updates in Focus at PFE, BMY, RHHBY, SNY

    Pfizer's (PFE) tafamidis application gets FDA's priority review. Regulatory updates for Roche's (RHHBY) and Bristol-Myers'(BMY) cancer combination drugs in focus.

  • Kitov Pharma's Stock Up on Anti-Cancer Candidate Findings
    Zacks5 months ago

    Kitov Pharma's Stock Up on Anti-Cancer Candidate Findings

    Shares of Kitov Pharma (KTOV) soar about 169% as the company's anti-cancer candidate, NT219 shows positive results.

  • GlobeNewswire5 months ago

    Kitov Announces Pricing of $6 Million Registered Direct Offering

    TEL-AVIV, Israel , Jan. 16, 2019 (GLOBE NEWSWIRE) --  Kitov Pharma Ltd. (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company, today announced that it has entered into definitive agreements with institutional investors providing for the issuance of 3,428,572 American Depositary Shares (ADS) at a purchase price of $1.75 per ADS in a registered direct offering. Kitov will also issue unregistered warrants to purchase up to 2,571,430 ADSs. The ADSs described above were offered pursuant to a shelf registration statement on Form F-3 (File No. 333-215037), which was declared effective by the United States Securities and Exchange Commission (the “SEC”) on December 14, 2016.

  • ACCESSWIRE5 months ago

    4 Healthcare Stocks Seeing Gains On Wednesday (1/16/19)

    CORAL GABLES, FL / ACCESSWIRE / January 16, 2019 / The healthcare industry is predicated on the notion that as diseases become more advanced and difficult to treat, companies responsible for creating treatment options will rise to the occasion to assist patients suffering from said ailments. As healthcare companies work to develop new methods for bettering the care provided to their patients, the industry, in its entirety, will unite to meet the demands and needs of consumers in the space looking for qualitative healthcare. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Microbot Medical Inc (MBOT), Kitov Pharma Ltd (KTOV), and Teladoc Health Inc (TDOC) are 4 healthcare stocks representing companies invested in creating the best quality treatments for their patients.

  • Kitov Pharmaceuticals News: KTOV Stock Up on Anti-Cancer Drug Findings
    InvestorPlace5 months ago

    Kitov Pharmaceuticals News: KTOV Stock Up on Anti-Cancer Drug Findings

    In the latest Kitov Pharmaceuticals news (NASDAQ:KTOV), the company's stock was skyrocketing on Monday as one of its anti-cancer drugs has yielded encouraging results. Source: Images Money via Flickr (Modified) The Israel-based company announced today the new findings from its NT219 treatment to battle cancer, which it has been studying alongside researchers from the Hebrew University of Jerusalem. The treatment reportedly has high affinity and selective binding to its target proteins. The drug's development is being led by Hadas Reuveni, who is the Chief Technology Officer at Kitov's subsidiary TyrNovo Ltd., as well as Dr. Galia Blum and Dr. Ofra Moshel from the Hebrew University. This team managed to showcase how the NT219 binds directly to Insulin Receptor Substrates (IRS) 1/2 and also to the Signal Transducer and Activator of Transcription 3 (STAT3). InvestorPlace - Stock Market News, Stock Advice & Trading Tips Both of these are known modulators that help to propel tumor survival, metastasis and resistance to drugs. New data shows that NT219 only needs to be exposed to cancerous cells for a short period of time to trigger irreversible shutdown of these pathways, which ultimately leads to a long-term anti-cancer effect. "We are excited about the new data which demonstrate NT219's unique mechanism of action. NT219, a new and promising concept in cancer therapy, is designed to prevent, reverse, and delay resistance to anti-cancer drugs," said Kitov CEO, Isaac Israel. KTOV stock is soaring a whopping 124.7% on Tuesday following the anti-cancer drug findings from the company. ### More From InvestorPlace * Morgan Stanley: 7 Risky Stocks to Sell Now * 10 Stocks You Can Set and Forget (Even In This Market) * The 7 Best Stocks in the Entrepreneur Index Compare Brokers The post Kitov Pharmaceuticals News: KTOV Stock Up on Anti-Cancer Drug Findings appeared first on InvestorPlace.

  • GlobeNewswire5 months ago

    New Data on Kitov’s NT219 Demonstrates its Unique Mechanism of Action and Anti-Cancer Effect

    Kitov Pharma (NASDAQ/TASE: KTOV), an innovative pharmaceutical company, today announced new findings from its ongoing collaboration with researchers from the Hebrew University  of Jerusalem. The data reveal NT219’s high affinity and selective binding to its target proteins. Hadas Reuveni, Ph.D., Chief Technology Officer at Kitov’s subsidiary, TyrNovo Ltd., in collaboration with Dr. Galia Blum and Dr. Ofra Moshel from the Hebrew University demonstrated that NT219 binds directly to Insulin Receptor Substrates (IRS) 1/2 and to the Signal Transducer and Activator of Transcription 3 (STAT3), both known modulators of tumor survival, metastasis and drug resistance.

  • ACCESSWIRE5 months ago

    4 Healthcare Stocks Making Moves On Monday (1/7/19)

    CORAL GABLES, FL / ACCESSWIRE / January 7, 2019 / The healthcare industry is predicated on the notion that as diseases become more advanced and difficult to treat, companies responsible for creating treatment options will rise to the occasion to assist patients suffering from said ailments. Given that the world's population is consistently increasing, and resources are diminishing, access to healthcare presents a dire need for consumers on a global scale. As healthcare companies work to develop new methods for bettering the care provided to their patients, the industry, in its entirety, will unite to meet the demands and needs of consumers in the space looking for qualitative healthcare.

  • ACCESSWIRE5 months ago

    4 Healthcare Stocks Gaining Speed on Thursday (1/3/19)

    CORAL GABLES, FL / ACCESSWIRE / January 3, 2019 / The health care industry is booming with companies determined to use inventive approaches to develop quality treatment options for patients around the ...

  • GlobeNewswire5 months ago

    Kitov Signs Marketing and Distribution Agreement for its Lead Product Consensi™ in the U.S. with Coeptis Pharmaceuticals

    Kitov Pharma (NASDAQ/TASE: KTOV), an innovative pharmaceutical company, today announced it has signed an exclusive marketing and distribution agreement with Coeptis Pharmaceuticals for the U.S. market. Coeptis will commercialize Kitov’s combination drug, Consensi™, intended to simultaneously treat osteoarthritis pain and hypertension.